Long-acting erythropoietin: clinical studies and potential uses in neonates

被引：13

作者：

Ohls, RK ^{[1
]}

Dai, AH ^{[1
]}

机构：

[1] Univ New Mexico, Dev Hematopoiesis Lab, Dept Pediat Neonatol, Albuquerque, NM 87131 USA

来源：

CLINICS IN PERINATOLOGY | 2004年 / 31卷 / 01期

关键词：

D O I：

10.1016/j.clp.2004.03.006

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Aranesp (darbepoietin alfa) is a biologically modified form of recombinant human erythropoietin (rHuEpo). Two additional carbohydrate-binding sites give Aranesp a half-life about three times that of rHuEpo. Extensive studies in adults and early studies in children indicate that Aranesp can be administered far less frequently than rHuEpo with an equivalent erythropoietic effect. This article reviews these studies and reports on the in vitro effects of Aranesp on human fetal and neonatal erythroid progenitors.

引用

页码：77 / +

页数：14

共 32 条

[1] Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis [J].

Allon, M ;

Kleininan, K ;

Walczyk, M ;

Kaupke, C ;

Messer-Mann, L ;

Olson, K ;

Heatherington, AC ;

Maroni, BJ .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (05) :546-555

[2] Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. [J].

Casadevall, N ;

Nataf, J ;

Viron, B ;

Kolta, A ;

Kiladjian, J ;

Martin-Dupont, P ;

Michaud, P ;

Papo, T ;

Ugo, V ;

Teyssandier, I ;

Varet, B ;

Mayeux, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (07) :469-475

[3] Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin [J].

Casadevall, N .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 :37-41

[4] Clinical experience with darbepoietin alfa (NESP) in children undergoing hemodialysis [J].

De Palo, T ;

Giordano, M ;

Palumbo, F ;

Bellantuono, R ;

Messina, G ;

Colella, V ;

Caringella, AD .

PEDIATRIC NEPHROLOGY, 2004, 19 (03) :337-340

[5] Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin [J].

Egrie, JC ;

Dwyer, E ;

Browne, JK ;

Hitz, A ;

Lykos, MA .

EXPERIMENTAL HEMATOLOGY, 2003, 31 (04) :290-299

[6]

Egrie JC, 1997, BLOOD, V90, P243

[7] Development and characterization of novel erythropoiesis stimulating protein (NESP) [J].

Egrie, JC ;

Browne, JK .

BRITISH JOURNAL OF CANCER, 2001, 84 (Suppl 1) :3-10

[8] A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy [J].

Glaspy, J ;

Jadeja, JS ;

Justice, G ;

Kessler, J ;

Richards, D ;

Schwartzberg, L ;

Rigas, J ;

Kuter, D ;

Harmon, D ;

Prow, D ;

Demetri, G ;

Gordon, D ;

Arseneau, J ;

Saven, A ;

Hynes, H ;

Boccia, R ;

O'Byrne, J ;

Colowick, AB .

BRITISH JOURNAL OF CANCER, 2001, 84 (Suppl 1) :17-23

[9] A randomized, active-control, pilot trial of front loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease [J].

Glaspy, JA ;

Jadeja, JS ;

Justice, G ;

Fleishman, A ;

Rossi, G ;

Colowick, AB .

CANCER, 2003, 97 (05) :1312-1320

[10]

Glaspy JA, 2002, ONCOLOGY-NY, V16, P23

← 1 2 3 4 →